These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 27979961

  • 41. [Comparison of quantitative detection of BCR::ABL1 p210 transcript levels: a multicenter study].
    Zhao CT, Ni CR, Lin YN, Ma XL, Wu QS, Wang F, Han XX, Liu F, Xu Y, Liu HX, Chen J, Ru K, Zhu MH.
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul 08; 53(7):672-677. PubMed ID: 38955697
    [Abstract] [Full Text] [Related]

  • 42. Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
    Tbakhi A, Pettay J, Sreenan JJ, Abdel-Razeq H, Kalaycio M, Hoeltge G, Miller ML, Tubbs RR.
    Am J Clin Pathol; 1998 Jan 08; 109(1):16-23. PubMed ID: 9426513
    [Abstract] [Full Text] [Related]

  • 43. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
    Moore FR, Rempfer CB, Press RD.
    Methods Mol Biol; 2013 Jan 08; 999():1-23. PubMed ID: 23666687
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients.
    Alikian M, Ellery P, Forbes M, Gerrard G, Kasperaviciute D, Sosinsky A, Mueller M, Whale AS, Milojkovic D, Apperley J, Huggett JF, Foroni L, Reid AG.
    J Mol Diagn; 2016 Mar 08; 18(2):176-89. PubMed ID: 26857065
    [Abstract] [Full Text] [Related]

  • 48. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.
    Crampe M, Haslam K, Kelly J, Conneally E, Langabeer SE.
    Hematol Oncol Stem Cell Ther; 2017 Jun 08; 10(2):85-88. PubMed ID: 27013275
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
    Miyanishi S, Umeki K, Hayashi T, Fukutsuka K, Okumura A, Kishimori C.
    Rinsho Byori; 2003 Oct 08; 51(10):1023-9. PubMed ID: 14653203
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood.
    Lee YK, Lee DW, Kim YL, Lee S, Min CK, Kim YJ, Oh IH, Kim TG, Kim CC, Kim DW.
    Int J Hematol; 2002 Aug 08; 76(2):180-5. PubMed ID: 12215018
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Arpinati M, Tolomelli G, Bochicchio MT, Castagnetti F, Amabile M, Bandini G, Bonifazi F, Stanzani M, Rosti G, Martinelli G, Baccarani M.
    Biol Blood Marrow Transplant; 2013 May 08; 19(5):735-40. PubMed ID: 23333776
    [Abstract] [Full Text] [Related]

  • 56. [Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR].
    Moravcová J, Brdicka R.
    Cas Lek Cesk; 2005 May 08; 144(1):32-7. PubMed ID: 15789779
    [Abstract] [Full Text] [Related]

  • 57. Development of a sensitive, highly controlled assay for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia.
    Hessner MJ, Roth MS, Drobyski WR, Baxter-Lowe LA.
    Genet Anal Tech Appl; 1994 May 08; 11(4):90-4. PubMed ID: 7857690
    [Abstract] [Full Text] [Related]

  • 58. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
    Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC.
    Blood; 2000 Jan 01; 95(1):62-6. PubMed ID: 10607685
    [Abstract] [Full Text] [Related]

  • 59. Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia.
    Kim Y, Kim S, Lee JM, Ahn A, Yoo JW, Lee JW, Cho B, Chung NG, Kim Y, Kim M.
    Front Pediatr; 2022 Jan 01; 10():928136. PubMed ID: 35967571
    [Abstract] [Full Text] [Related]

  • 60. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
    Zagaria A, Anelli L, Coccaro N, Tota G, Casieri P, Cellamare A, Impera L, Brunetti C, Minervini A, Minervini CF, Delia M, Cumbo C, Orsini P, Specchia G, Albano F.
    Virchows Arch; 2015 Sep 01; 467(3):357-63. PubMed ID: 26149409
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.